Lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion
Initial LEN therapy rapidly alleviates airway stenosis in advanced thyroid cancer with laryngotracheal invasion, offering a non-invasive alternative to emergency procedures under careful monitoring for fistula formation. LEN is especially valuable as a bridging therapy during the genetic testing period in ATC.
Authors
- Hiroshi Katoh (ORCID: https://orcid.org/0000-0002-2453-6278)
- Takafumi Sangai (ORCID: https://orcid.org/0000-0003-2052-0479)
- Takaaki Tokito (ORCID: https://orcid.org/0000-0002-8429-2287)
- Mariko Kikuchi
- Yuka Ozawa
- Riku Okamoto
Institutions
- Kitasato University Hospital (JP)
Publication Details
- Journal
- European Thyroid Journal
- Published
- 2025-09-18
- DOI
- https://doi.org/10.1530/etj-25-0212
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00